Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation

Author(s): Ghada Abdelmoemen, Samy Abdelkader Khodeir, Ahmed Nabil Zaki, Maha Kassab, Sabry Abou-Saif, Sherief Abd-Elsalam*.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets

Volume 19 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background & Aims: Insulin resistance is the real determinant of both Nonalcoholic fatty liver disease (NAFLD) and diabetes, and can facilitate the accumulation of triglycerides in the liver. Overexpression of hepassocin (HPS) increased the accumulation of hepatic fat and NAFLD activity scores (NAS) in mice. The aim of this study was to investigate the relationship between hepassocin and steatosis of the liver in diabetic patients with or without NAFLD in humans.

Methods: The study enrolled 60 patients plus 20 healthy controls that were divided into 4 groups: Group I: included 20 patients who were diagnosed as diabetes mellitus type 2, Group II: included 20 patients who were diagnosed as nonalcoholic fatty liver disease (NAFLD), Group III: included 20 patients who were diagnosed as diabetes type 2 and NAFLD, and Group IV (control group): included 20 healthy person or controls who were matched in age and sex with patients group. All patients and controls were subjected to full history taking, thorough clinical examination, laboratory investigations including measurement of serum hepassocin in peripheral blood by ELISA technique.

Results: There was a significant overexpression of serum hepassocin in patients with type 2 diabetes and NAFLD patients (Group 3) more than diabetic patients (Group 1) and even more than non-alcoholic fatty liver disease (Group 2).

Conclusion: This study provides evidence that increased HPS may facilitate increased hepatic lipid accumulation with NAFLD and type 2 diabetes.

Keywords: Serum hepassocin, NAFLD, diabetes mellitus, insulin resistance, metabolic syndrome, nonalcoholic fatty liver disease.

[1]
American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care, 2009 b, 32(1), S62-S67.
[2]
Pucci, G.; Alcidi, R.; Tap, L.; Battista, F.; Mattace-Raso, F.; Schillaci, G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol. Res., 2017, 120, 34-42.
[3]
Day, C.P. From fat to inflammation. Gastroenterology, 2006, 130, 207-210.
[4]
Florez, H.; Silva, E.; Fernández, V.; Ryder, E.; Sulbarán, T.; Campos, G.; Calmón, G.; Clavel, E.; Castillo-Florez, S.; Goldberg, R. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res. Clin. Pract., 2005, 69(1), 63-77.
[5]
Abdeldyem, S.M.; Goda, T.; Khodeir, S.A.; Abou Saif, S.; Abd-Elsalam, S. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J. Clin. Lipidol., 2017, 11(4), 915-919.
[6]
Lu, F.H.; Ou, H.Y.; Wu, H.T.; Hung, H.C.; Wu, J.S.; Yang, Y.C.; Chang, C.J. Serum Horm. Metab. Res.,2018, 50, 397-402.hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver disease. Diabetes Management, 2014, 4, 255-261.
[7]
Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Bugianesi, E.; Lenzi, M.; McCullough, A.J.; Natale, S.; Forlani, G.; Melchionda, N. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes, 2001, 50, 1844-1850.
[8]
Sheng, X.; Che, H.; Ji, Q.; Yang, F.; Lv, J.; Wang, Y.; Xian, H.; Wang, L. The relationship between liver enzymes and insulin resistance in type 2 diabetes patients with nonalcoholic fatty liver disease. Horm. Metab. Res., 2018, 50, 397-402.
[9]
Lazo, M.; Hernaez, R.; Bonekamp, S.; Kamel, I.R.; Guallar, E.; Clark, J.M. Nonalcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ, 2011, 343, d6891.
[10]
Cao, M.M.; Xu, W.X.; Li, C.Y.; Cao, C.Z.; Wang, Z.D.; Yao, J.W.; Yu, M.; Zhan, Y.Q.; Wang, X.H.; Tang, L.J.; Chen, H.; Li, W.; Ge, C.H.; Yang, X.M. Hepassocin regulates cell proliferation of the human hepatic cells L02 and hepatocarcinoma cells through different mechanisms. J. Cell. Biochem., 2011, 112(10), 2882-2890.
[11]
Wu, H.T.; Lu, F.H.; Ou, H.Y.; Su, Y.C.; Hung, H.C.; Wu, J.S.; Yang, Y.C.; Wu, C.L.; Chang, C.J. The role of hepassocin in the development of non-alcoholic fatty liver disease. J. Hepatol., 2013, 59(5), 1065-1072.
[12]
Loria, P.; Lonardo, A.; Anania, F. Liver and diabetes. A vicious circle. Hepatol. Res., 2013, 43(1), 51-64.
[13]
Kleiner, D.E.; Brunt, E.M.; Van Natta, M.; Behling, C.; Contos, M.J.; Cummings, O.W.; Ferrell, L.D.; Liu, Y.C.; Torbenson, M.S.; Unalp-Arida, A.; Yeh, M.; McCullough, A.J.; Sanyal, A.J. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41, 1313-1321.
[14]
Yu, H.T.; Yu, M.; Li, C.Y.; Zhan, Y.Q.; Xu, W.X.; Li, Y.H.; Li, W.; Wang, Z.D.; Ge, C.H.; Yang, X.M. Specific expression and regulation of hepassocin in the liver and down-regulation of the correlation of HNF1alpha with decreased levels of hepassocin in human hepatocellular carcinoma. J. Biol. Chem., 2009, 284(20), 13335-13347.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 2
Year: 2019
Page: [185 - 188]
Pages: 4
DOI: 10.2174/1871530318666180716100543
Price: $58

Article Metrics

PDF: 18
HTML: 1